Onco Actu du 19 février 2019

	2.5 ETIOLOGIE - GÈNES
Research Uncovers the Genetic Causes of Aggressive Leukemia in Children [Memorial Sloan Kettering Cancer Center] “We found that these pediatric leukemias have extensive changes in their DNA that lead to the production of fusion genes, complex deletions, and translocations — where pieces of DNA get moved around,” he adds. Previous research from Dr. Kentsis’s lab looked at the role of similar genome rearrangements in many types of solid tumors in children.
	4.10 DÉP., DIAG. & PRONO. - POUMON
Graphene biosensor could provide early lung cancer diagnosis, research shows [University of Exeter] “The new biosensors which we have developed show that graphene has significant potential for use as an electrode in e-nose devices. For the first time, we have shown that with suitable patterning graphene can be used as a specific, selective and sensitive detector for biomarkers."
	4.2 DÉP., DIAG. & PRONO. - GÉNOME
Myriad Applauds the American Society of Breast Surgeons New Guidelines Recommending Genetic Testing for All People with Breast Cancer [Myriad] These new ASBrS guidelines are based on research recently published by the Targeted Medical Education (TME) Breast Care Network in the Journal of Clinical Oncology.
	5.1 TRAITEMENTS - PRÉ-CLINIQUE
Advancing therapy by measuring the 'games' cancer cells play [EurekAlert!] In a paper recently published in Nature Ecology and Evolution, Dr. Scott and his collaborators develop a first-in-class "game assay" which they used to directly quantify and describe the eco-evolutionary interactions between sensitive and resistant tumor cells in an experimental model of non-small cell lung cancer cells sensitive to targeted therapy.
	5.10 TRAITEMENTS - ESSAIS
Progress in the treatment of aggressive brain tumors [University of Bonn] “This is a major success,” says Herrlinger. “Since the initial approval of temozolomide in 2005, chemotherapy of glioblastoma had made virtually no progress.” The researchers are now trying to further improve the therapy, for example by combining three drugs.
	5.12 IMMUNOTHÉRAPIES
Why Some Brain Tumors Respond to Immunotherapy [Columbia University] Nonresponsive tumors had more mutations in a gene called PTEN, which led to higher levels of macrophages, immune cells that usually help the body fight bacteria and other invaders. But in glioblastoma, the macrophages release a number of growth factors that promote the survival and spread of cancer cells.
	5.5.3 ASCO (PROSTATE)
Bayer, Orion prostate cancer drug cuts risk of metastasis or death by more than 50% in key study [EndPoints] The German drugmaker agreed to develop the AR inhibitor darolutamide with Finland’s Orion in 2014, the same year the Phase III ARAMIS trial commenced. The class of drugs is designed to block the growth of cancer cells by binding to the androgen receptor and inhibiting its function.
	6. LUTTE CONTRE LES CANCERS
Making the case to double NIH [The Cancer Letter] With so much at stake, NIH should receive increases in funding commensurate with the impending health and financial crisis, yet the federal budget allocates a mere one percent towards medical research. Doubling the NIH budget within 10 years is the only way to avert a devastating health—and health care cost—crisis.
	6.10 POLITIQUES
BREXIT WARNING: UK patients visiting EU for treatment face BMA alert - hundreds at risk [Express] More than 5,400 NHS England patients have gone to the EU for treatment through the EU Directive Route after it was introduced in 2013. Under the directive, patients pay for treatment in Europe and are refunded by the NHS if their re-imbursal application is successful. Patients often pay for treatment abroad when faced with huge waiting times on the NHS.
	6.7 DMP, BIG DATA & APPLIS
National Data Guardian: a consultation on priorities [GOV.UK] We want to hear views on the key priorities for the National Data Guardian for Health and Social Care, as the role moves to a new phase.